Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tuberculosis Research Blood Bank

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Rany Condos, MD, New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00212498
First received: September 13, 2005
Last updated: September 3, 2014
Last verified: September 2014
  Purpose

To create a Tuberculosis Research Blood Bank for future molecular genetics and serological studies


Condition Intervention
Tuberculosis
Procedure: Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:
  • Develop TB Blood Bank [ Time Frame: Long-Term ] [ Designated as safety issue: No ]
    To develop a bank of blood samples (serum, plasma, buffy coat DNA) and urine from patients infected with TB. This blood and urine will be used for future molecular genetics studies. Demographic data will be collected and samples will be stored by number. The banked specimens will be evaluated in an attempt to identify susceptibility genes in TB disease. Specifically, expression of the human Bcg gene that codes for resistance to M. tuberculosis will be evaluated and its expression correlated expression with gender, race, clinical TB characteristics. Each patient will have a unique identifier and therefore data generated from this analysis will not be linkable to the patient.


Estimated Enrollment: 50
Study Start Date: November 2006
Estimated Study Completion Date: January 2015
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
TB diagnosis Procedure: Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies
Blood sample

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

TB patients

Criteria

50 patients per year

Inclusion Criteria:

  • TB suspect with positive sputum smear
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00212498

Locations
United States, New York
NYU School of Medicine Division of Pulmonary and Critical Care Medicine
New York, New York, United States, 10016
Sponsors and Collaborators
New York University School of Medicine
Investigators
Principal Investigator: Rany Condos, MD NYU School of Medicine
  More Information

No publications provided

Responsible Party: Rany Condos, MD, Assistant Professor of Medicine, New York University School of Medicine
ClinicalTrials.gov Identifier: NCT00212498     History of Changes
Other Study ID Numbers: 11354 (previously 4424)
Study First Received: September 13, 2005
Last Updated: September 3, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Tuberculosis
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections

ClinicalTrials.gov processed this record on November 25, 2014